BC Extra | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
BC Innovations | Feb 22, 2019
Targets & Mechanisms

Solid checkpoint for CARs

PD-L1 family member B7-H3 could put CAR T cells in play for a slew of difficult-to-treat solid tumors, including pediatric cancers that lack targeted therapies, according to a pair of preclinical studies published this year....
BC Innovations | Feb 13, 2019
Distillery Therapeutics

Cancer

INDICATION: Bone cancer; sarcoma; brain cancer Mouse studies suggest CAR T cells targeting B7-H3 could help treat pediatric osteosarcoma, Ewing sarcoma and brain cancer. In tumor samples from 388 patients with pediatric solid tumors and...
BC Week In Review | Feb 10, 2014
Company News

MacroGenics, Servier deal

MacroGenics said Servier exercised its option to acquire rights to develop and commercialize MGD006 outside of North America, Japan, South Korea and India. MacroGenics, which will retain rights in those regions, will receive a $20...
BC Week In Review | Sep 2, 2013
Clinical News

MGA271: Phase I started

MacroGenics began the dose-expansion portion of an open-label, U.S. Phase I trial to evaluate 15 mg/kg IV MGA271 given for the first 3 weeks of a 4-week cycle in about 45 patients. The portion will...
BioCentury | Oct 15, 2012
Strategy

At home with Servier

Rather than follow in the footsteps of other foundation-backed mid-size European pharmas that have largely concentrated on a single therapeutic area and looked to new markets for growth, Servier has determined its path to sustainability...
BC Week In Review | Sep 24, 2012
Company News

MacroGenics, Servier deal

MacroGenics granted Servier an exclusive option to license rights to develop and commercialize preclinical mAbs against three undisclosed cancer targets outside North America, Japan, Korea and India. MacroGenics will receive $20 million up front and...
BC Extra | Sep 21, 2012
Company News

MacroGenics, Servier in second cancer mAb option deal

MacroGenics Inc. (Rockville, Md.) granted Servier (Neuilly-sur-Seine, France) an exclusive option to license rights to develop and commercialize preclinical mAbs against three undisclosed cancer targets outside North America, Japan, Korea and India. MacroGenics will receive...
BC Week In Review | Sep 17, 2012
Company News

ImaginAb, MacroGenics deal

The companies partnered to develop in vivo imaging agents for autoimmune diseases and cancer. ImaginAb will develop a clinical imaging agent based on an undisclosed MacroGenics' anti-CD3 antibody as a patient selection tool for ongoing...
BioCentury | Jun 18, 2012
Product Development

Immune springboard

A spate of Phase III data events over the next two years will give a readout on how correctly the lessons learned five years ago about cancer immunotherapies targeting T cell responses have been put...
Items per page:
1 - 10 of 13